AstraZeneca’s IL‑33 biologic Tozorakimab hits multiple Phase III successes – Meet them this September

Altesa BioSciences advances Vapendavir for rhinovirus‑triggered COPD exacerbations

GSK expands its COPD pipeline with a novel siRNA therapy (EMP‑012)

Emerging COPD treatments highlight biologics, bronchoscopic procedures & stem‑cell approaches

ReAlta’s pegtarazimod showing early promise for acute COPD exacerbations in phase 2

GSK’s Nucala gains UK backing, expanding COPD biologic access with NICE recommendation

Windward Bio and Harbour Biomed announce first Phase II dosing in SIRIUS trial for novel COPD antibody therapy

TidalSense secured $19 million to commercialise its AI-powered COPD diagnostic technology

Day

Hour

Minute

Second

Advancing Precision in COPD Clinical Trials Through CT Imaging Endpoints

2:30 pm - Tuesday 15th September 2026

Maximizing the value of CT imaging by driving consistency and accuracy in centralized reads
Opportunities and challenges in deploying CT-based imaging in global COPD clinical trials
Emerging opportunities to integrate imaging endpoints with functional, biological, and patient-reported outcomes for earlier, more meaningful insights